Annual Reports Agreement

In accordance with the Terms of Use of these websites it is forbidden to use the photographs contained in the Annual Reports posted on the websites for any purposes other than for exclusively personal and non-commercial use and to duplicate, alter, modify, rearrange or otherwise tamper with the photographs contained in the Annual Reports and disseminate any such altered, modified, rearranged or otherwise affected photographs. You may retrieve and display the content of the Annual Reports including photographs on a computer or mobile telephone screen, print individual pages on paper (but not photocopy them) and store such pages in electronic form on disk or on your mobile telephone (but not on any server or other storage device connected to for your personal, non-commercial use only.)

Do you agree with the above stated terms of use of the Annual Reports?

Yes   No

Downloading

    SOTIO presents Immunotherapy Research in Prostate, Ovarian and Head and Neck Cancer at 2014 ASCO Annual Meeting
    05/29/2014

    SOTIO, a biotechnology company belonging to the PPF Group, announced that it will present four abstracts highlighting clinical progress and research results on DCVAC/PCa and DCVAC/OvCa treatments and head and neck squamous cell carcinoma at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

    SOTIO is developing new medical therapies, focusing on the treatment of cancer and autoimmunity diseases. The company’s current focus is predominantly on an Active Cellular Immunotherapy (ACI) for prostate cancer patients, called DCVAC/PCa, and for patients with ovarian cancer, called DCVAC/OvCa. In addition, research and clinical development is investigating potential uses in patients with lung cancer and head and neck cell carcinoma.

    SOTIO will present the following studies evaluating its dendritic cell-based vaccines DCVAC/PCa, DCVAC/OvCa and head and neck cancer experimental data at the 2014 ASCO Annual Meeting:

    • Combined chemoimmunotherapy of castrate-resistant prostate cancer with dendritic-cell based vaccine DCVAC/PCa
    • Cancer immunotherapy of patients with biochemical relapse of prostate cancer using dendritic cell-based vaccine DCVAC/PCa
    • Autologous dendritic cell vaccination (DCVAC/OvCa) added to standard care therapy in three open-label randomized phase 2 studies in women with advanced stage ovarian cancer: This poster describes SOTIO’s Phase II program in three distinct stages of ovarian cancer.
    • Distinct patterns of intratumoral immune cell infiltrates in patients with HPV-positive versus HPV-negative head and neck squamous cell carcinoma

     

    Radek Špíšek, Chief Scientific Officer of SOTIO said: “ASCO's acceptance of our abstracts provides an opportunity to share the preliminary results of SOTIO’s research and clinical development with the world’s leading oncologists, key opinion-formers in immunotherapy and the expert media. Having
    three posters and one presentation at the world’s most prestigious conference on cancer treatments is an excellent result for a company in SOTIO’s early stage of development.”

    SOTIO will also have an exhibition booth at ASCO for those seeking further information (Booth number 22146).

    With over 30,000 attendees, the ASCO Annual Meeting is one of the largest and most prestigious
    educational and scientific events in the oncology community. The five-day event provides a venue for physicians and scientists to present research results to a global audience of oncology professionals. Clinical trial results and updates presented at ASCO's Annual Meeting represent the extent of progress made each year in the fight against cancer.

    Back to Press Releases